

## **Yulia Ron, M.D.**

**Place of Work:** Department of Gastroenterology and Liver Diseases  
Tel Aviv Medical Center  
6 Weizman St.  
Tel Aviv 64239, Israel  
Phone: 972-3-6874280  
Fax: 972-3-6974460

**Home Address:** 32 Alroi St. Herzliya  
**Telephone:** +972-52-4266460  
**Email:** [Yuliar@tasmc.health.gov.il](mailto:Yuliar@tasmc.health.gov.il)  
[Yuliar11@gmail.com](mailto:Yuliar11@gmail.com)

**Date & Place of Birth:** April 10, 1976, Astana, Kazakhstan

**Immigration to Israel:** 1999

### **A. Education**

- 1993 - 1999** Medical University, Almaty, Kazakhstan
- 2002 – 2007** Residency in Internal Medicine, Department of Medicine "H",  
Tel Aviv Sourasky Medical Center. Head of department: Prof. M. Topilsky
- **2004** Nephrology - Department, Tel Aviv Sourasky Medical Center. Director: Dr. Doron Schwartz
  - **2005** Division of Imaging, Tel Aviv Sourasky Medical Center.  
Director: Prof. Moshe Graif
  - **2005 - 2006** Clinical Research, Dep. of Gastroenterology, Tel-Aviv, Sourasky Medical Center. Subject: Differential Diagnosis of Neoplastic Pancreatic Cysts: The Role of EUS with Guided FNA under the supervision of Dr. Erwin M. Santo
- 2007 - 2010** Tel Aviv Medical Center (Prof. Z. Halpern), Tel Aviv, Israel  
Fellowship in Gastroenterology, Department of Gastroenterology
- 2011 - present** Tel Aviv Sourasky Medical Center, Dept. of Gastroenterology and Liver Diseases, Senior gastroenterologist, IBD Service  
Biologic therapy for IBD patients, IBD infusion center  
Multidisciplinary clinics as Transitional IBD clinic  
IBD and pregnancy/ IBD and reproduction
- 2012** Clinical IBD Training - Leuven, Belgium (Dr. Severine Vermeire).

## **B. ACADEMIC AND PROFESSIONAL EXPERIENCE**

- 2010 - 2018** Tutor of 3<sup>th</sup> year students of Sackler School of medicine
- 2011 - 2018** Training of Israeli and an American medical student
- 2010 - present** International workshops tutor (Kazakhstan/Russian/Turkmenian/Italian) of gastroenterology, infectious diseases specialists & colorectal surgeons.

## **C. Membership in professional societies**

- 2006 - 2018** Israeli Gastroenterological Association, Israel
- 2012 -2019** ECCO

## **D. Certification/Licensure (Israel)**

- 2007** Internal Medicine
- 2010** Gastroenterology and Hepatology

## **E. Active Participation in Scientific Meetings**

- 2007** "Internal Medicine Division Annual Conference" Tues. 27.3.07 Hotel "Dan" Tel Aviv  
Differential Diagnosis of Neoplastic Pancreatic Cysts: The Role of EUS with Guided FNA. **Y.Ron**, M. Leshno, O.Barkai, E. Santo, (Oral presentation)
- 2012** Israel Gastroenterological Association annual meeting Eilat Israel. January 2012 Infliximab for moderate to severe ulcerative colitis: short and long-term therapy and predictors of response  
**Ron Y**, Yanai H, Ben Yehoyada M, Meirovithz E, Yahav L, Yeshurun D, Santo E, Dotan I (Oral presentation)
- 2012** European Crohn's and Colitis Organisation ECCO, 7th Congress of ECCO Barcelona, Spain, February 2012  
Infliximab for moderate to severe ulcerative colitis: Short and long-term therapy and predictors of response  
**Ron Y**, Yanai H, Ben Yehoyada M, Meirovithz E, Yahav L, Yeshurun D, Santo E, Dotan I (poster presentation)

Yulia Ron, MD

- 2012** Digestive disease week, San Diego, CA  
Infliximab for moderate to severe ulcerative colitis:  
short and long-term effect and predictors of response  
**Ron Y**, Yanai H, Ben Yehoyada M, Meirovithz E, Yahav L, Yeshurun D,  
Santo E, Dotan I. (poster presentation)
- 2014** Third International Conference of the Digestive Disease Institute of Shaare Zedek  
Medical Center, Jerusalem, Featuring IBD and pregnancy. Case presentation (Oral  
presentation) **Ron Y**
- 2015** Digestive disease week, Chicago, USA  
Transitional care in Inflammatory Bowel Disease  
Anat Yerushalmy-Feler, **Ron Y**, Iris Dotan, Shlomi Cohen,  
Santo E, Dotan I. (poster presentation)
- 2018** Central Asian Gastroenterology week 2018- **Ron Y**  
Advances in IBD.  
Infusion Centers in Israel – Modern models of Multidisciplinary care for IBD
- 2018** Investigators meeting in Moscow -Gilead- **Ron Y**  
The evolving IBD treatment landscape
- 2018** Master-class in Israel- **Ron Y**  
Modern guidelines for the management and treatment of IBD in adults
- 2019** Master -class in Kazakhstan - **Ron Y**  
Multidisciplinary approach is a key to best treatment of care IBD

## **F. Participation in clinical trials**

12 years, Clinical Phase of Trial (II-IV).

Indication of Trial: IBD, Diverticulitis– Sub Investigator

## **G. Scientific Publications**

1. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.  
Ben-Horin S, Mazor Y, Yanai H, **Ron Y**, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y.  
Aliment Pharmacol Ther. 2012 Mar.
2. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.  
Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, **Ron Y**, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude CJ, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PD, Chaparro M, Ben-Horin S.  
Inflamm Bowel Dis. 2012 Jan

Yulia Ron, MD

3. Ensure preparation and capsule endoscopy: A two-center prospective study  
Eva Niv, Baruch Ovadia, **Ron Y**, Ervin Santo, Zamir Halpern, Zvi Fireman World J Gastroenterol 2013 February 28
4. Transitional Care in Inflammatory Bowel Disease: A Single Center Experience **Ron Y**, Anat Yerushalmy-Feler, Ayala Nachum, Iris Dotan, Shlomi Cohen Gastroenterology 2015 April
5. Henit Yanai, Lev Lichtenstein, Amit Assa, Yoav Mazor, Batia Weiss, Arie Levine, **Ron Y**, Uri Kopylov et al  
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab  
Clinical Gastroenterology and hepatology, 2015 March
6. Henit Yanai, Liat Malinarsky, **Ron Y**, Merav Ben Yehoyada, Dror Yeshurun, Erwin M. Santo, Iris Dotan  
The Questionable Value of Infliximab Trough Levels During Prolonged Maintenance Therapy.  
Gastroenterology 2012 May
7. Infliximab for Moderate to Severe Ulcerative Colitis: Short and Long-Term Effects and Predictors of Response.  
**Ron Y**, Henit Yanai, Merav Ben Yehoyada, Elhanan Meirovitch, Lior Yahav, Dror Yeshurun, Erwin Santo, Iris Dotan  
Gastroenterology. 2012 May (Abstract)
8. Patient factors that increase infliximab clearance and shorten half life in inflammatory bowel disease a population pharmacokinetic study  
Iris Dotan, **Ron Y**, Henit Yanai, Diane R Mould et al  
Inflamm. Bowel Dis 2014 Dec
9. Infliximab-Related Infusion Reactions Systematic Review  
Lev Lichtenstein, **Ron Y**, Shmuel Kivity, Shomron Ben-Horin, Eran Israeli, Gerald M Fraser, Iris Dotan, Yehuda Chowers, Ronit Confino-Cohen, Batia Weiss  
Jornal of Crohn's and Colitis 2015 June
10. Adolescent transition clinic in inflammatory bowel disease: quantitative assessment of self-efficacy skills.  
Yerushalmy-Feler, Anat, **Ron Yulia**, Matalon Shay, Dali-levy Margalit, Dotan Iris, Cohen Shlomi  
European Journal of Gastroenterology & Hepatology, July 2017
11. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience  
Kopylov U\*, **Ron Y**\*, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. (\*equal authorship)  
Inflamm Bowel Dis. 2017 Mar

Yulia Ron, MD

12. Novel prep-less X-ray imaging capsule for colon cancer screening: a feasibility study.  
Gluck N, Half EE, Bieber V, Schwartz D, **Ron Y**, Gralnek I, Klein A, Lachter J, Levy MS, Moshkowitz M, Arber N.  
Gut. 2018 May
13. Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease - feasibility study.  
Eliakim R, Cristiano Spada, Alon Lapidus, Inbal Eyal, **Yulia Ron** et al, Henit Yanai and Samuel Adler. Endoscopy Int Open
14. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients with Inflammatory Bowel Disease  
A Multicenter Retrospective European Study.  
Kopylov U, Verstockt B, Biedermann L, Pugliese D, Sonnenberg E, **Ron Y**, Kucharzik T, Roblin X, Ungar B, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Dotan I, Ferrante M  
Inflamm Bowel Dis. 2018 Oct